Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

[1]  Fidel Ramírez,et al.  Computing topological parameters of biological networks , 2008, Bioinform..

[2]  Thomas Lengauer,et al.  Conformational analysis of alternative protein structures , 2007, Bioinform..

[3]  A. Kwong,et al.  Phenotypic and Structural Analyses of Hepatitis C Virus NS3 Protease Arg155 Variants , 2007, Journal of Biological Chemistry.

[4]  Thomas Lengauer,et al.  IRECS: A new algorithm for the selection of most probable ensembles of side‐chain conformations in protein models , 2007, Protein science : a publication of the Protein Society.

[5]  Tara L. Kieffer,et al.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.

[6]  H. Chu,et al.  [609] TELAPREVIR (VX 950)-RESISTANT VARIANTS EXHIBIT REDUCED REPLICATION CAPACITY COMPARED TO WILD-TYPE HCV IN VIVO AND IN VITRO , 2007 .

[7]  S. Zeuzem,et al.  SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. , 2007, Gastroenterology.

[8]  Stefan Schmitt,et al.  Do structurally similar ligands bind in a similar fashion? , 2006, Journal of medicinal chemistry.

[9]  S. Zeuzem,et al.  Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. , 2006, Gastroenterology.

[10]  X. Tong,et al.  Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. , 2006, Antiviral research.

[11]  F. G. Njoroge,et al.  Novel Inhibitors of Hepatitis C NS3—NS4A Serine Protease Derived from 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic Acid. , 2006 .

[12]  S. Tamura,et al.  Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. , 2006, Journal of medicinal chemistry.

[13]  S. Lemon,et al.  Mutations Conferring Resistance to SCH6, a Novel Hepatitis C Virus NS3/4A Protease Inhibitor , 2006, Journal of Biological Chemistry.

[14]  N. Butkiewicz,et al.  SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells , 2006, Antimicrobial Agents and Chemotherapy.

[15]  A. Kwong,et al.  Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. , 2006, Infectious disorders drug targets.

[16]  Philip E. Bourne,et al.  The RCSB PDB information portal for structural genomics , 2005, Nucleic Acids Res..

[17]  Cathy H. Wu,et al.  The Universal Protein Resource (UniProt): an expanding universe of protein information , 2005, Nucleic Acids Res..

[18]  M. Manns,et al.  Viral Kinetics in Patients with Chronic Hepatitis C Treated with the Serine Protease Inhibitor Biln 2061 , 2005, Antiviral therapy.

[19]  Christophe Combet,et al.  Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes , 2005, Hepatology.

[20]  X. Forns,et al.  Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. , 2004, Gastroenterology.

[21]  M. Murcko,et al.  Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants. , 2004, Bioorganic & medicinal chemistry letters.

[22]  B. G. Rao,et al.  Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization. , 2004, Bioorganic & medicinal chemistry letters.

[23]  P. Marcellin,et al.  Peginterferon-2a and Ribavirin Combination Therapy in Chronic Hepatitis C , 2004, Annals of Internal Medicine.

[24]  Robert C. Edgar,et al.  MUSCLE: multiple sequence alignment with high accuracy and high throughput. , 2004, Nucleic acids research.

[25]  B. G. Rao,et al.  Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants. , 2003, Bioorganic & medicinal chemistry letters.

[26]  Steven R. LaPlante,et al.  An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus , 2003, Nature.

[27]  Paul Bamborough,et al.  Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease. , 2003, Organic letters.

[28]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[29]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[30]  Berk Hess,et al.  GROMACS 3.0: a package for molecular simulation and trajectory analysis , 2001 .

[31]  F. Narjes,et al.  Hepatitis C Virus Serine Protease Inhibitors: Current Progress and Future Challenges , 2001 .

[32]  R. Bartenschlager,et al.  Enhancement of Hepatitis C Virus RNA Replication by Cell Culture-Adaptive Mutations , 2001, Journal of Virology.

[33]  B. Malcolm,et al.  Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity , 2001, Proteins.

[34]  M Rarey,et al.  Detailed analysis of scoring functions for virtual screening. , 2001, Journal of medicinal chemistry.

[35]  J. Gesell,et al.  Solution structure and dynamics of the single-chain hepatitis C virus NS3 protease NS4A cofactor complex. , 2001, Journal of molecular biology.

[36]  U. Koch,et al.  Hepatitis C virus protease inhibitors: current progress and future challenges. , 2001, Current medicinal chemistry.

[37]  R. Cortese,et al.  The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. , 1999, Journal of molecular biology.

[38]  Andrew E. Torda,et al.  The GROMOS biomolecular simulation program package , 1999 .

[39]  Ying Li,et al.  Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 Å resolution structure in a hexagonal crystal form , 1998, Protein science : a publication of the Protein Society.

[40]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[41]  Gapped BLAST and PSI-BLAST: A new , 1997 .

[42]  C. Sander,et al.  Positioning hydrogen atoms by optimizing hydrogen‐bond networks in protein structures , 1996, Proteins.

[43]  Manolo Gouy,et al.  SEAVIEW and PHYLO_WIN: two graphic tools for sequence alignment and molecular phylogeny , 1996, Comput. Appl. Biosci..

[44]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[45]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[46]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[47]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[48]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.